376 results about "Antibody targeting" patented technology

The invention discloses an antibody-modified lipid nanoparticle, a preparation method thereof and application of the antibody-modified lipid nanoparticle as a targeting carrier. The invention provides lipid nanoparticles coupled with an antibody and loaded with nucleic acid. The lipid nanoparticles are characterized in that raw materials of the lipid nanoparticles consist of ionizable lipid, phospholipid, steroidal lipid, PEG lipid and PEG-Mal lipid, the PEG lipid is C16-PEG2k, and the PEG-Mal lipid is C16-PEG2k-Mal, and the PEG-Mal lipid is C16-PEG2k-Mal. The method aims at the key scientific problems of low delivery efficiency, insufficient targeting and the like in the field of in-vivo hematopoietic stem / progenitor cell gene therapy at present. The invention develops a lipid nanoparticle delivery system based on antibody modification, provides a modular antibody targeted delivery platform with high universality, and shows huge clinical transformation potential.

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

The invention relates to a monoclonal antibody targeting RSV F protein, and a related product and application thereof. The monoclonal antibody (AD5) or the antigen binding fragment of the monoclonal antibody is specifically bound with the Site III antigen epitope of the RSV F protein. The antibody AD5 disclosed by the invention has the characteristics of targeting high-conservative epitope (Site III) and having high neutralizing activity, and overcomes the main defect that the neutralizing activity is not high when the existing listed antibody targets the high-conservative epitope.

The invention belongs to the technical field of biological medicine, and provides an antibody targeting Gn glycoprotein on the surface of a severe fever with thrombocytopenia syndrome virus and application of the antibody. The antibodies N2C1 and N2D2 and the bispecific antibody obtained by modification based on the antibodies N2C1 and N2D2 provided by the invention can be specifically combined with Gn glycoprotein on the surface of the severe fever with thrombocytopenia syndrome virus, and show a strong neutralization protection effect in in-vitro cell and in-vivo animal experiments. Therefore, the N2C1 and N2D2 antibodies and the bispecific antibody obtained by modification can be used as drugs for preventing or treating severe fever with thrombocytopenia syndrome virus infection.

The present invention relates to a novel antibody targeting B7-H3 or an antigen-binding fragment thereof, a chimeric antigen receptor (CAR) comprising same, an immune cell comprising the CAR, and uses thereof. The CAR-T cells according to the present invention have low toxicity and excellent antitumor activity, and thus can be effectively used in immune cell treatment for cancer treatment.

Embodiments described herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, and pomalidomide, to the subject to treat the multiple myeloma.

The present invention relates to an antibody targeting ActRIIB and an application thereof. Specifically, the invention provides an ActRIIB binding molecule, which comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the function of identifying and binding ActRIIB. The antibody can reduce animal fat content and / or increase animal muscle content.

The invention discloses a nano antibody of a targeted ubiquitin ligase RNF149 and an application of the nano antibody of the targeted ubiquitin ligase RNF149. The nano antibody is composed of a heavy chain variable region containing CDR1, CDR2 and / or CDR3, the CDR1 comprises an amino acid sequence as shown in SEQ ID NO: 4, 8 or 12, the CDR2 comprises an amino acid sequence as shown in SEQ ID NO: 5, 9 or 13, and the CDR3 comprises an amino acid sequence as shown in SEQ ID NO: 6, 10 or 14. The humanized nano antibody of the targeted ubiquitin ligase RNF149, provided by the invention, has relatively high affinity with RNF149 extracellular domain protein, and can be used for detecting the RNF149 and carrying out related researches.

The invention relates to an antibody or an antigen fragment of a targeted human CD7 and application of the antibody or the antigen fragment. The antibody and the CD7-CAR based on the antibody fragment have extremely strong affinity with a CD7 antigen molecule, and a blocking molecule containing the antibody can almost completely block the expression of the CD7 molecule on the cell surface without influencing the normal amplification of T cells, so that the self-killing of the CD7-CAR-T cells can be effectively avoided. The CD7-CAR-T cell constructed on the basis of the single-domain antibody of the targeted human source CD7 has a strong killing effect on a target cell.

An engineered trophoblast that expresses a cell surface molecule that specifically recognizes NKp46, the cell surface molecule comprising at least an antibody targeting NKp46 and a transmembrane domain. The invention discloses a cell culture medium and a method for amplifying NK cells. Compared with unengineered trophoblasts, the engineered trophoblasts are used for activating NK cells, and the amplification capacity of the NK cells and the killing activity of tumor cells can be enhanced.

The application discloses an antibody targeting DLL3 and application thereof, and relates to the field of biological medicines. Specific anti-DLL3 nanobodies are screened in the embodiment of the application, and a bispecific antibody constructed from the anti-human DLL3 nanobody or humanized nanobody and an anti-human CD3 antibody is prepared, the obtained bispecific antibody has good antitumor activity, can be applied to preparation of at least one drug for preventing or treating a DLL3 expression abnormality related tumor or cancer disease including small cell lung cancer, and has wide application.

Provided are an anti-CAIX single-domain antibody and a VHH chain thereof, as well as related coding sequence, expression vector and host cell; also provided are a production method for said CAIX single-domain antibody and an application thereof.

The invention belongs to the technical field of gene engineering and protein engineering, and particularly relates to a fully human antagonistic antibody taking a lactylated STAT6 protein as a target spot and application of the fully human antagonistic antibody. According to the present invention, the completely humanized antagonistic antibody using the lactylated STAT6 protein as the target spot is screened from the human scFv phage antibody library, the amino acid sequence of the completely humanized antagonistic antibody is represented by SEQ ID NO: 1, and the completely humanized antagonistic antibody has the specificity of the targeted lactylated STAT6 protein, and has the application prospect in preparation of the product for diagnosis, treatment or alleviation of sepsis immunosuppression.

Provided are an antibody targeting Trop2, an antibody-drug conjugate, and use thereof. The provided antibody targeting Trop2 is capable of specifically binding to a target cell expressing human Trop2, has high affinity with same, is capable of entering the cell by means of endocytosis and inhibiting tumor growth or progression, and can be used for treating, preventing, and ameliorating conditions in a subject associated with abnormal expression of Trop2 (e.g., breast cancer, urothelial carcinoma, and non-small cell lung cancer).

The present invention provides humanized antibodies targeting CD7, as well as multispecific antibodies, chimeric antigen receptors, antibody conjugates, pharmaceutical compositions and kits comprising the same, and their use in the diagnosis / treatment / prevention of diseases associated with CD7 expression.

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The application discloses a konjac glucomannan-based temperature-sensitive and targeted microsphere probiotic embedding method and relates to the technical field of biochemistry, and comprises the following steps: step 1, a free radical copolymerization method is used to synthesize copolymer microspheres; step 2, amino modification is performed to prepare amino groups; step 3, the amino groups are grafted onto the copolymer microspheres through an epoxy ring-opening reaction to prepare copolymer microspheres; step 4, monoclonal antibody copolymer microspheres are prepared; and step 5, the copolymer microspheres are mixed with probiotic hyphae to complete embedding of the probiotics, and monoclonal antibody-probiotic copolymer microspheres are obtained. The konjac glucomannan-based temperature-sensitive and targeted microsphere probiotic embedding method is a four-component composite carrier which is innovative in terms of a skeleton, temperature sensitivity, crosslinking and antibody targeting, and is innovative in a step-by-step grafting and temperature-sensitive and targeted synergistic process, solves the pain points of poor protection and difficult targeted release of the probiotics, and realizes precise and intelligent delivery.

Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.

The present disclosure provides novel neutralizing potent antibodies targeting S100 protein, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting PD-L1 cross binding of human and cynomolgus monkeys and application of the single-domain antibody. The single-domain antibody disclosed by the invention has the specificity of resisting PD-L1 of human and cynomolgus monkeys, and shows relatively strong binding efficacy in the binding detection of PD-L1 target protein or PD-L1 overexpression cells; in the detection of blocking PD-1 / PD-L1 functions, a part of the single-domain antibodies even show a blocking effect which is obviously superior to that of Atezolizumab, so that the single-domain antibodies prepared by the invention can be used for diagnosis, treatment and prognosis detection of PD-L1 positive tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

Provided are a novel antithrombotic antibody targeting a blood coagulation factor FIXa-FVIIIa binding site and an application thereof.SOLUTION: The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts an antithrombotic effect. The antibody of the present invention has an appropriate antithrombotic performance and a large effective therapeutic concentration window, but does not increase the bleeding risk, which can achieve the need for moderate antithrombosis and effectively avoid the bleeding problem caused by excessive action in clinical applications. The present invention also discloses methods of screening for drugs that target the FIXa-FVIIIa binding site.SELECTED DRAWING: Figure 1A

The presently disclosed subject matter provides antibodies, or antigen-binding fragments thereof, that bind to CD3, and methods of using such antibodies, or antigen-binding fragments thereof, including, but not limited to, multispecific antibodies, scFv antibody domains. The disclosure also encompasses antibodies having a sequence-defined heavy chain variable subunit and a sequence-defined light chain variable subunit, the subunits having a sequence-defined CDR.

The invention relates to a nano antibody targeting claudin 18.2 and application thereof, and relates to the technical field of immunology and molecular biology. An amino acid sequence of a complementary determining region of the nano antibody for targeting claudin 18.2 comprises a CDR1 (Complementary Determining Region) as shown in SEQ ID NO: 1, a CDR2 (Complementary Determining Region) as shown in SEQ ID NO: 5 and a CDR3 (Complementary Determining Region) as shown in SEQ ID NO: 12. According to the invention, an alpaca immune bacteriophage display library is constructed, a series of nano antibody molecules specifically targeting claudin 18.2 are screened from the alpaca immune bacteriophage display library, and functions and applications of the nano antibody are verified at CLDN18.2 antigen protein and CLDN18.2 target cell levels.

This invention belongs to the field of biomedicine, and relates to single-domain antibodies, more specifically to a humanized single-domain antibody targeting VEGF and its applications. The amino acid sequence of the single-domain antibody includes three complementarity-determining regions (CDR1-CDR3) and four backbone regions (FR1-FR4). This invention also provides a recombinant protein containing the single-domain antibody, a nucleic acid molecule encoding the single-domain antibody or recombinant protein, a vector containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or vector, and the application of the single-domain antibody or recombinant protein in the preparation of drugs targeting VEGF to treat diseases.

This invention discloses an antibody targeting a specific protein of *Lactobacillus* and its applications. The monoclonal antibody of this invention is any one of monoclonal antibody 1B3, monoclonal antibody 3B5, monoclonal antibody 2E5, and monoclonal antibody 3D8, which respectively recognize proteins Srt A, Cps C, ENO 1, and Fts Z. The magnetic bead antibody conjugate is prepared by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of this invention can specifically enrich *Lactobacillus* bacteria with high enrichment efficiency and simple operation. It can be applied to the identification of metabolites of *Lactobacillus* bacteria, as well as their qualitative and quantitative analysis.

The present application provides a monoclonal antibody targeting human carcinoembryonic antigen CEACAM5 / 6, and a bispecific antibody capable of simultaneously targeting human carcinoembryonic antigen CEACAM5 / 6 and human CD47, a preparation method and applications. Specifically, it relates to an anti-human CD47 antibody and antigen-binding fragments thereof capable of simultaneously (1) specifically binding to human CD47 protein and blocking its binding to SIRPalpha, thereby thus blocking the inhibitory effect of CD47 on SIRPalpha-expressing macrophages; (2) specifically binding to human carcinoembryonic protein CEACAM5 / 6. The present application also relates to a preparation method and uses of the bispecific antibody.

This invention belongs to the field of antigen recognition technology, specifically relating to an antibody or its antigen-binding fragment that targets and recognizes mCD155, and its applications. The antibody targeting and recognizing mCD155 includes sequences as shown in SEQ ID NO:8 and SEQ ID NO:16 or as shown in SEQ ID NO:24 and SEQ ID NO:32; it has a strong binding affinity to the mCD155-his protein; and CAR-T cells constructed based on this antibody exhibit excellent killing (apoptotic) activity against mCD155-mediated tumors.

The application belongs to the technical field of biotechnology, and discloses a nano antibody targeting B cell BCMA and application thereof. The amino acid sequences of the complementarity determining regions CDR1-CDR3 of the nano antibody are selected from SEQ ID NO. 1-12. The nano antibody provided by the application can specifically bind to B cells in human blood, especially activated plasma cells, so as to eliminate B cells producing pathological antibodies. Compared with traditional antibodies, the nano antibody provided by the application has a smaller molecular weight, high stability, low cost, easy expression and high expression amount, and is suitable for large-scale production. The nano antibody is combined with a solid-phase carrier in the application, so that B cells in blood can be targeted and eliminated, the number of B cells in blood of patients can be reduced in a short time, and the antibody level can be reduced, thereby improving the quality of life, reducing complications, and providing a new treatment option for patients who are ineffective or intolerant to traditional treatment.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of an antibody two-dimensional code. The invention creatively develops a method for generating an antibody two-dimensional code (Ab-QRcode) only based on an antibody sequence without antigen information. The antibody two-dimensional code generated by the method can describe species specificity, variety and targeting specificity information of the antibody, and each antibody has a unique two-dimensional code which is unique and different from other antibodies. Based on the two-dimensional code, the target specificity of the antibody can be distinguished, and the antibody can be clustered according to the difference between the target specificity of the antibody, so that the clustering of the antibody for identifying the same or similar antigen can be realized.